Literature DB >> 25124550

Zolpidem and the risk of Parkinson's disease: a nationwide population-based study.

Yu-Wan Yang1, Teng-Fu Hsieh2, Chia-Hui Yu3, Yung-Sung Huang4, Ching-Chih Lee5, Tsung-Huang Tsai6.   

Abstract

BACKGROUND: This nationwide population-based study investigated the risk of Parkinson's disease (PD) after zolpidem use in patients with sleep disturbance using the National Health Insurance Research Database (NHIRD) in Taiwan.
MATERIAL AND METHODS: In total, 59,548 adult patients newly diagnosed with sleep disturbance and who used zolpidem were recruited as the study cohort, along with 42,171 subjects who did not use zolpidem as a comparison cohort from 2002 to 2009. Each patient was monitored for 5 years, and those who subsequently had PD were identified. A Cox proportional hazards model was used to compare the risk of PD between the study and comparison cohorts after adjusting for possible confounding risk factors.
RESULTS: The patients who received zolpidem had a higher cumulative rate of PD than those who did not receive zolpidem during the 5-year follow-up period (1.2% vs. 0.5%, P < 0.001). The adjusted hazard ratios were 1.10 (95% CI, 0.88-1.37), 1.41 (95% CI, 1.17-1.72), and 1.27 (95% CI, 1.05-1.55) for zolpidem use with 28-90, 91-365, and more than 365 cumulative defined daily doses (cDDDs), respectively, compared to those who did not use zolpidem.
CONCLUSIONS: Among the patients with sleep disturbance, zolpidem use increased the risk of PD after 5 years of follow-up. Further mechanistic research of zolpidem effect in PD is needed.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Insomnia; Parkinson's disease; Risk; Sleep disturbance; Zolpidem

Mesh:

Substances:

Year:  2014        PMID: 25124550     DOI: 10.1016/j.jpsychires.2014.07.003

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  15 in total

1.  Cyproheptadine use in hepatocellular carcinoma.

Authors:  Mao-Chih Hsieh; Wei-Hua Lee; Alexander Th Wu; Jyh-Ming Chow; Chia-Lun Chang; Kevin Sheng-Po Yuan; Szu-Yuan Wu
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  Sleep and affective disorders in relation to Parkinson's disease risk among older women from the Women's Health Initiative.

Authors:  Hind A Beydoun; Jiu-Chiuan Chen; Nazmus Saquib; Michelle J Naughton; May A Beydoun; Aladdin H Shadyab; Lauren Hale; Alan B Zonderman
Journal:  J Affect Disord       Date:  2022-06-22       Impact factor: 6.533

3.  Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson's Disease.

Authors:  Daphna Laifenfeld; Chen Yanover; Michal Ozery-Flato; Oded Shaham; Michal Rosen-Zvi; Nirit Lev; Yaara Goldschmidt; Iris Grossman
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

4.  Relationship between Erectile Dysfunction, Comorbidity, and Parkinson's Disease: Evidence from a Population-Based Longitudinal Study.

Authors:  Yuwan Yang; Hsinho Liu; Tienhuang Lin; Yuhung Kuo; Tengfu Hsieh
Journal:  J Clin Neurol       Date:  2017-07       Impact factor: 3.077

5.  Potential therapeutic effects of N-butylidenephthalide from Radix Angelica Sinensis (Danggui) in human bladder cancer cells.

Authors:  Sheng-Chun Chiu; Tsung-Lang Chiu; Sung-Ying Huang; Shu-Fang Chang; Shee-Ping Chen; Cheng-Yoong Pang; Teng-Fu Hsieh
Journal:  BMC Complement Altern Med       Date:  2017-12-06       Impact factor: 3.659

6.  Sleep apnea and the subsequent risk of Parkinson's disease: a 3-year nationwide population-based study.

Authors:  Ping-Song Chou; Chiou-Lian Lai; Yii-Her Chou; Wei-Pin Chang
Journal:  Neuropsychiatr Dis Treat       Date:  2017-03-30       Impact factor: 2.570

7.  Statins improve outcomes of nonsurgical curative treatments in hepatocellular carcinoma patients.

Authors:  Li-Li Wu; Mao-Chih Hsieh; Jyh-Ming Chow; Shing-Hwa Liu; Chia-Lun Chang; Szu-Yuan Wu
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

8.  Increased risk of Parkinson disease with diabetes mellitus in a population-based study.

Authors:  Yu-Wan Yang; Teng-Fu Hsieh; Chia-Ing Li; Chiu-Shong Liu; Wen-Yuan Lin; Jen-Huai Chiang; Tsai-Chung Li; Cheng-Chieh Lin
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

Review 9.  Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease.

Authors:  Antonio Daniele; Francesco Panza; Antonio Greco; Giancarlo Logroscino; Davide Seripa
Journal:  Parkinsons Dis       Date:  2016-05-17

10.  Metformin Use Correlates with Reduced Risk of Gallstones in Diabetic Patients: A 12-Year Follow-up Study.

Authors:  Kuan-Fu Liao; Hsun-Yang Chuang; Shih-Wei Lai
Journal:  Front Pharmacol       Date:  2017-10-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.